ARS Pharmaceuticals, Inc.
SPRY
$8.54
$0.526.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -19.25% | -13.58% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -19.25% | -13.58% | |||
| Cost of Revenue | 10.68% | -12.29% | |||
| Gross Profit | -34.78% | -14.24% | |||
| SG&A Expenses | 20.43% | -19.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.09% | -18.84% | |||
| Operating Income | -45.05% | 22.05% | |||
| Income Before Tax | -46.41% | 19.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -46.69% | 19.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -46.69% | 19.21% | |||
| EBIT | -45.05% | 22.05% | |||
| EBITDA | -45.56% | 22.26% | |||
| EPS Basic | -46.30% | 19.39% | |||
| Normalized Basic EPS | -63.87% | 28.06% | |||
| EPS Diluted | -45.57% | 18.99% | |||
| Normalized Diluted EPS | -63.87% | 28.06% | |||
| Average Basic Shares Outstanding | 0.27% | 0.22% | |||
| Average Diluted Shares Outstanding | 0.27% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||